ArticleVirchows Archiv : an international journal of pathology2015
CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
Article in Virchows Archiv : an international journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis.PloS one · 2018Pooled it
- Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.International journal of cancer · 2018Trial
- Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- Efficacy and safety of Pola-R-mini-CHP therapy in patients aged ≥80 years with CD5-positive diffuse large B-Cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- [Chinese expert consensus on the diagnosis and treatment of CD5-positive diffuse large B-cell lymphoma (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.Hematological oncology · 2025Observational
- Recent advances in CD5Annals of hematology · 2024Review
- Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.Virchows Archiv : an international journal of pathology · 2024Article
- Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma.Frontiers in oncology · 2022Article
- Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.Frontiers in oncology · 2022Article
- Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified.Blood advances · 2021Article
- Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China.Frontiers in oncology · 2021Article
- Prognostic significance of aberrant CD5 expression in B-cell leukemia.Oncology reviews · 2019Article
- Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.PloS one · 2019Article
- CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients.Open medicine (Warsaw, Poland) · 2018Article
- Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.Chinese journal of cancer · 2017Article
- Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies.Hematology. American Society of Hematology. Education Program · 2017Review
- Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms.Experimental and therapeutic medicine · 2017Article
- Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.European journal of nuclear medicine and molecular imaging · 2017Review
- New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015-December 2015.Journal of hematopathology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Age over 60 years is one of the five parameters of the International Prognostic Index (IPI), which is the most important clinical prognostic predictor in DLBCL. A previous study on German DLBCL patients over 60 years of age showed that immunoblastic morphology, but not germinal center B cell-like (GCB)/non-GCB subtype, correlated with short survival. We collected 174 DLBCL cases over 60 years of age in Taiwan and performed immunophenotyping and detection of Epstein-Barr virus (EBV)-encoded RNA (EBER) by in situ hybridization. Of the cases, 5.2 % were positive for CD5 and 5.7 % positive for EBER. Neither immunoblastic morphology nor GCB/non-GCB subtype correlated with survival. In univariate analysis, adverse prognostic factors included IPI ≥ 3 (P < 0.000001), B symptoms (P = 0.000075), bone marrow/peripheral blood involvement (P = 0.017), EBER positivity (P = 0.0013), and CD5 positivity (P = 0.016). In multivariate analysis, CD5 positivity was the only independent adverse prognostic factor (HR = 3.16; 95 % CI = 1.34-7.47; P = 0.0087) in addition to IPI ≥ 3 (HR = 3.07; 95 % CI = 1.84-5.11; P = 0.000018). Surprisingly, despite an overall 5.2 % incidence of central nervous system (CNS) relapse in our patients, none of the CD5+ cases experienced CNS relapse (P = 1.00). This is in stark contrast to the more frequent CNS relapse in Japanese CD5+ DLBCL patients. EBER positivity was associated with IPI ≥ 3 (P = 0.010), stage III-IV (P = 0.0082), and B symptoms (P = 0.011). In multivariate analysis, EBER positivity was not an independent adverse prognostic factor (P = 0.81), its effect being due likely to accompanying adverse clinical parameters.
Indexed as
Identifiers
26369546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.